Oragenics has completed a key study for their new concussion drug, ONP-002. This drug is designed to be delivered through the nose, which could help it reach the brain quickly after a head injury. The recent study shows that the drug successfully targets areas inside the nose that are connected to the brain. This makes it more likely to reach and treat the brain after a concussion. Intranasal casting studies are valued by the FDA for pharmaceuticals delivered via the nasal passage and accept such studies in FDA submissions. Oragenics is now preparing to move forward with human testing in patients who come to the emergency room with a concussion, aiming to give the first dose of the drug within 8 hours of the injury.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OGEN:
- Oragenics Executive Compensation and Shareholder Meeting Updates
- Oragenics to sell 8.1M shares at 55c in public offering
- Biotech Alert: Searches spiking for these stocks today
- Oragenics completes spray-dried formulation, filling in nasal device for ONP-002
- Oragenics files to sell 2.4M shares of common stock